Tandem Diabetes Care Inc (NASDAQ:TNDM) was down 7.9% on Tuesday . The company traded as low as $34.00 and last traded at $35.25. Approximately 1,681,127 shares changed hands during mid-day trading, a decline of 29% from the average daily volume of 2,383,763 shares. The stock had previously closed at $38.28.

A number of equities research analysts have recently weighed in on TNDM shares. Lake Street Capital lifted their price target on shares of Tandem Diabetes Care from $35.00 to $65.00 and gave the company a “buy” rating in a research report on Monday, August 20th. Zacks Investment Research downgraded shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research report on Saturday, October 6th. Robert W. Baird downgraded shares of Tandem Diabetes Care from an “outperform” rating to a “neutral” rating in a research report on Friday, September 14th. BidaskClub upgraded shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 23rd. Finally, Oppenheimer set a $57.00 price target on shares of Tandem Diabetes Care and gave the company a “buy” rating in a research report on Friday, November 9th. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $44.75.

The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -2.74 and a beta of 0.52.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, November 1st. The medical device company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.28). The firm had revenue of $46.30 million during the quarter, compared to the consensus estimate of $42.71 million. Tandem Diabetes Care had a negative net margin of 93.07% and a negative return on equity of 204.32%. The business’s revenue was up 71.5% compared to the same quarter last year. During the same period last year, the business earned ($3.09) earnings per share. Equities research analysts anticipate that Tandem Diabetes Care Inc will post -1.31 earnings per share for the current fiscal year.

In other news, Director Richard P. Valencia acquired 1,300 shares of the firm’s stock in a transaction that occurred on Monday, November 5th. The shares were acquired at an average cost of $37.75 per share, with a total value of $49,075.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kim D. Blickenstaff sold 198,000 shares of Tandem Diabetes Care stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $37.01, for a total transaction of $7,327,980.00. The disclosure for this sale can be found here. Company insiders own 9.30% of the company’s stock.

A number of large investors have recently made changes to their positions in TNDM. US Bancorp DE grew its stake in shares of Tandem Diabetes Care by 397.8% during the third quarter. US Bancorp DE now owns 2,489 shares of the medical device company’s stock worth $107,000 after buying an additional 1,989 shares during the last quarter. Tower Research Capital LLC TRC bought a new stake in shares of Tandem Diabetes Care during the third quarter worth $109,000. Meeder Asset Management Inc. grew its stake in shares of Tandem Diabetes Care by 1,921.6% during the third quarter. Meeder Asset Management Inc. now owns 2,709 shares of the medical device company’s stock worth $116,000 after buying an additional 2,575 shares during the last quarter. BlueMountain Capital Management LLC bought a new stake in shares of Tandem Diabetes Care during the third quarter worth $140,000. Finally, Legal & General Group Plc bought a new stake in shares of Tandem Diabetes Care during the second quarter worth $147,000. 71.60% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Tandem Diabetes Care (TNDM) Trading Down 7.9%” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/tandem-diabetes-care-tndm-trading-down-7-9/2663043.html.

About Tandem Diabetes Care (NASDAQ:TNDM)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Story: How To Calculate Debt-to-Equity Ratio

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.